CE Mark for Orsiro Mission drug-eluting stent system.- Biotronik
Related news and insights
New, long-term follow-up data from the BIOSOLVE-IV real-world registry strengthens the clinical evidence for Biotronik’s Magmaris Resorbable Magnesium Scaffold (RMS) as a therapy option for patients with coronary artery disease.
Abbott announced its XIENCE stent has received CE Mark in Europe for shorter duration of dual anti-platelet therapy (DAPT) – as short as 28 days, the shortest indication available in the world – for patients with high bleeding risk (HBR).
Biotronik’s ultrathin-strut stent, Orsiro, demonstrated superiority over Xience DES for target lesion failure (TLF) at 24 months, according to new follow-up data from the BIOSTEMI trial.